Abstract
Overview of Clinical Intelligence Report Series
Austin Research Analytics Group' s (ARAG) Clinical Intelligence Report Series provides clients within the pharmaceutical and biotechnology industry with detailed competitive information to facilitate key analysis and decision-making. Clients utilize the report as an resource to support key decisions including:
- Analyzing the overall depth and breadth of the competitive landscape within a therapeutic area
- Assessing target product profiles of key current and future competitors
- Benchmarking competitor clinical trial designs and results
- Developing clinical analogues to support go-no-go decisions
- Identifying clinical hurdles posed by competitors
- Designing clinical trials more effectively to maximize a product' s penetration
Reports contain synthesized information and analysis of clinical development activities for key marketed and pipeline products within multiple therapeutic categories and generally include the following data points:
- Product Overview: Mechanism of Action, Developing Companies, Indications and Phase of Development.
- Clinical Trial Assessments: Detailed evaluations of completed and ongoing
competitor studies that capture key elements of the study protocol including:
- Trial design
- Start and end dates
- Study size and patient type
- Number of participating sites
- Dosing regimen
- Endpoints
- Safety and efficacy results
Table of Contents
Section 1: Executive Summary
- Psoriasis Disease Overview
- Classification of Psoriasis
- Disease Epidemiology: U.S. & European Prevalence
- Disease Epidemiology-Patient Segmentation
- Psoriasis Treatment Paradigm
- Conventional Psoriasis Therapies
- Overview of Competitive Landscape
- Ongoing Psoriasis Clinical Trials
Section 2: The Current Market Leaders in Psoriasis
- Enbrel (etanercept)
- Remicade (infliximab)
- Humira (adalimumab)
- Raptiva
Section 3: Future Competitive Threats
- CNTO-1275
- Golimumab (CNTO-148)
- ABT-874
- Cimzia
- Zanolimumab
Section 4: Early Stage Development Programs: Products on the Radar
- BMS-582949
- Apremilast
- BIRT 2584XX
- AMG-714
- BCX-4208
- MEDI-545
Section 5: Appendix
- Disclaimer
- Report Licensing
